0 works0 citations0 h-index

Roberto Hegg

Universidade de São Paulo(BR)Federal Government of Brazil(BR)Hospital Pérola Byington(BR)Centro de Pesquisas Oncológicas(BR)

Publications by Year

Research Areas

HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Women's cancer prevention and management

Most-Cited Works

→ Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer(2018)4,264 cited
→ Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer(2011)2,495 cited
→ Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial(2020)1,743 cited
→ Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)(2013)1,241 cited
→ Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial(2020)1,030 cited

→ Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study(2020)

865 cited

→ Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer(2021)702 cited

→ Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial(2022)595 cited

→ Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study(2021)370 cited

→ Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial(2012)341 cited